Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer

In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody bevacizumab, several alternative anti-angiogenic treatment strategies for ovarian cancer patients have been evaluated in clinical trials. Apart from targeting extracellular receptors by the antibody aflibercept or the p...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Front Oncol
Autori principali: Mahner, Sven, Woelber, Linn, Mueller, Volkmar, Witzel, Isabell, Prieske, Katharina, Grimm, Donata, Keller-v Amsberg, Gunhild, Trillsch, Fabian
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2015
Soggetti:
Oncology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4593253/
https://ncbi.nlm.nih.gov/pubmed/26500886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2015.00211
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi